They systematically assessed an impressive 2,609 patients over four study sites, with 492 meeting their criteria for screening for JE virus (JEV). Of the cases of acute encephalitis (AES), their results confirm that 4% had JEV. It is also important to consider the patients with negative ELISA results for JEV; 472 (96%) of the patients had an unknown cause of their AES. ELISA testing is the method of choice for JEV, because viraemia is too transient for molecular methods, such as polymerase chain reaction, to be useful. There are data that show that IgM responses to JEV take between 7 and 10 days to develop. 3, 4 However, there are also data to suggest that an early low cerebrospinal fluid (CSF) immunoglobulin (Ig)M response may be suggestive of a poor outcome 5 ; thus, if the CSF IgM rise is only transient, it may be missed by single sampling. Accurate diagnostics in the field are notoriously difficult, but it is crucial that this problem is highlighted and that timing of samples is clearly described so as not to engender complacency about the real prevalence and incidence of JE in cases of AES.
The current World Health Organization (WHO) JE surveillance standards recommend a sample at ≥ 10 day of illness to confirm or exclude JEV. 6 Patients with early JEV ELISA negative samples should, thus, not be classified as JE negative but instead, as having JEV unknown status. Although it can be difficult to get the timing of the illness onset, it is preferable, where possible, to distinguish between JEV negative and JEV unknown, so that the JEV unknown cases can be excluded from any calculations of the proportion of cases caused by JEV. These data are helpful in informing government and funding bodies as to where to target JE vaccination programs. 
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